Literature DB >> 25667138

Should gastric cardia cancers be treated with esophagectomy or total gastrectomy? A comprehensive analysis of 4,996 NSQIP/SEER patients.

Jeremiah T Martin1, Angela Mahan1, Joseph B Zwischenberger1, Patrick C McGrath1, Ching-Wei D Tzeng2.   

Abstract

BACKGROUND: Category 1 guidelines emphasize multimodality therapy (MMT) for patients with gastric cardia cancer (GCC). These patients are often referred to thoracic surgeons for "esophagogastric junction" cancers rather than to abdominal surgeons for "proximal gastric" cancers. This study sought to determine the ideal surgical approach using national datasets evaluating morbidity/mortality (M/M) and overall survival (OS). STUDY
DESIGN: Patients with resected GCC were identified from the 2005 to 2012 ACS-NSQIP dataset and the 1998 to 2010 SEER dataset. Multivariate 30-day M/M analyses were performed using NSQIP. Survival analyses were derived from SEER and stratified by surgical approach.
RESULTS: There were 1,181 NSQIP patients with GCC included; 81.8% had esophagectomies and 18.1% had gastrectomies. Major postoperative M/M occurred in 33.2%/3.7% patients after gastrectomy vs 35.0%/2.4% after esophagectomy (p = 0.260). Although a major postoperative complication (odds ratio 12.8, p < 0.001) was an independent predictor of mortality on multivariate analysis, surgical approach was not. Of the 3,815 SEER patients included, 71.1% had esophagectomies and 28.9% had gastrectomies. Radiation use (surrogate for MMT) was administered more often with esophagectomy vs gastrectomy (42.9% vs 29.6%, p < 0.001). Unadjusted median overall survival (OS) favored esophagectomy (26.0 vs 21.0 months, p = 0.025). However, multivariate analysis confirmed age (hazard ratio [HR] 1.01), T/N stages (HR 1.12/1.91), and radiation use (HR 0.83, all p ≤ 0.018), but not surgical approach (HR 0.95, p = 0.259), as independent predictors of OS.
CONCLUSIONS: Tumor biology and MMT, rather than surgical approach, dictate oncologic outcomes for GCC. Therefore, the decision of esophagectomy vs gastrectomy for GCC should be based on proximal and distal tumor extent and the multidisciplinary strategy with the lower rate of complications and the higher rate of MMT completion.
Copyright © 2015 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25667138     DOI: 10.1016/j.jamcollsurg.2014.12.024

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  13 in total

1.  Is the transthoracic approach no longer a viable option for Siewert type II esophagogastric junction carcinoma?

Authors:  Hiroharu Yamashita; Yasuyuki Seto
Journal:  Transl Gastroenterol Hepatol       Date:  2016-03-16

Review 2.  Surgical approaches to adenocarcinoma of the gastroesophageal junction: the Siewert II conundrum.

Authors:  Andrew M Brown; Danica N Giugliano; Adam C Berger; Michael J Pucci; Francesco Palazzo
Journal:  Langenbecks Arch Surg       Date:  2017-08-12       Impact factor: 3.445

3.  Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy.

Authors:  Deep Pujara; Paul Mansfield; Jaffer Ajani; Mariela Blum; Elena Elimova; Yi-Ju Chiang; Prajnan Das; Brian Badgwell
Journal:  J Surg Oncol       Date:  2015-10-19       Impact factor: 3.454

Review 4.  [Differentiated surgical approach for adenocarcinoma of the gastroesophageal junction].

Authors:  W Schröder; R Lambertz; R van Hillegesberger; C Bruns
Journal:  Chirurg       Date:  2017-12       Impact factor: 0.955

5.  Thoracoscopic side-to-side esophagogastrostomy by use of linear stapler-a simplified technique facilitating a minimally invasive Ivor-Lewis operation.

Authors:  Tomoyuki Irino; Jon A Tsai; Jessica Ericson; Magnus Nilsson; Lars Lundell; Ioannis Rouvelas
Journal:  Langenbecks Arch Surg       Date:  2016-03-09       Impact factor: 3.445

6.  Defining the Impact of Surgical Approach on Perioperative Outcomes for Patients with Gastric Cardia Malignancy.

Authors:  Ryan W Day; Brian D Badgwell; Keith F Fournier; Paul F Mansfield; Thomas A Aloia
Journal:  J Gastrointest Surg       Date:  2015-09-28       Impact factor: 3.452

Review 7.  Oesophageal cancer.

Authors:  Elizabeth C Smyth; Jesper Lagergren; Rebecca C Fitzgerald; Florian Lordick; Manish A Shah; Pernilla Lagergren; David Cunningham
Journal:  Nat Rev Dis Primers       Date:  2017-07-27       Impact factor: 52.329

8.  Gastrectomy compared to oesophagectomy for Siewert II and III gastro-oesophageal junctional cancer in relation to resection margins, lymphadenectomy and survival.

Authors:  Joonas H Kauppila; Karl Wahlin; Jesper Lagergren
Journal:  Sci Rep       Date:  2017-12-19       Impact factor: 4.379

9.  Lymph node dissection for Siewert II esophagogastric junction adenocarcinoma: A retrospective study of 3 surgical procedures.

Authors:  Xiao-Feng Duan; Jie Yue; Peng Tang; Xiao-Bin Shang; Hong-Jing Jiang; Zhen-Tao Yu
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

10.  Optimal Extent of Transhiatal Gastrectomy and Lymphadenectomy for the Stomach-Predominant Adenocarcinoma of Esophagogastric Junction: Retrospective Single-Institution Study in China.

Authors:  Baoyu Zhao; Zhenzhan Zhang; Debin Mo; Yiming Lu; Yanfeng Hu; Jiang Yu; Hao Liu; Guoxin Li
Journal:  Front Oncol       Date:  2019-01-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.